138 related articles for article (PubMed ID: 35465844)
1. Alpha-mangostin as an inhibitor of GSK3β in triple-negative breast cancer.
Dewi C; Fristiohady A; Amalia R; Bunggulawa EJ; Muchtaridi M
J Biomol Struct Dyn; 2023 Jul; 41(10):4515-4521. PubMed ID: 35465844
[TBL] [Abstract][Full Text] [Related]
2. α-Mangostin and its derivatives against estrogen receptor alpha.
Mardianingrum R; Yusuf M; Hariono M; Mohd Gazzali A; Muchtaridi M
J Biomol Struct Dyn; 2022 Apr; 40(6):2621-2634. PubMed ID: 33155528
[TBL] [Abstract][Full Text] [Related]
3. Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative breast cancer.
Bashir Y; Noor F; Ahmad S; Tariq MH; Qasim M; Tahir Ul Qamar M; Almatroudi A; Allemailem KS; Alrumaihi F; Alshehri FF
J Biomol Struct Dyn; 2024; 42(3):1099-1109. PubMed ID: 37021492
[TBL] [Abstract][Full Text] [Related]
4. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
5. A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivatives.
Akash S; Aovi FI; Azad MAK; Kumer A; Chakma U; Islam MR; Mukerjee N; Rahman MM; Bayıl I; Rashid S; Sharma R
PLoS One; 2023; 18(10):e0283271. PubMed ID: 37824496
[TBL] [Abstract][Full Text] [Related]
6. Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor.
Chatterjee P; Karn R; Emerson IA; Banerjee S
Mol Biotechnol; 2024 Apr; 66(4):718-736. PubMed ID: 36732462
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.
Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S
J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337
[TBL] [Abstract][Full Text] [Related]
8. Exploring the composition of protein-ligand binding sites for cancerous inhibitor of PP2A (CIP2A) by inhibitor guided binding analysis: paving a new way for the Discovery of drug candidates against triple negative breast cancer (TNBC).
Ibitoye O; Ibrahim MAA; Soliman MES
J Recept Signal Transduct Res; 2023 Dec; 43(6):133-143. PubMed ID: 38166612
[TBL] [Abstract][Full Text] [Related]
9. Binding and stability of indirubin-3-monoxime in the GSK3β enzyme: a molecular dynamics simulation and binding free energy study.
Saravanan K; Hunday G; Kumaradhas P
J Biomol Struct Dyn; 2020 Mar; 38(4):957-974. PubMed ID: 30963817
[TBL] [Abstract][Full Text] [Related]
10. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
11. Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.
Mangangcha IR; Brojen Singh RK; Lebeche D; Ali S
J Biomol Struct Dyn; 2022 Oct; 40(17):7868-7884. PubMed ID: 33769184
[TBL] [Abstract][Full Text] [Related]
12. Proposed molecular mechanism of non-competitive inhibition using molecular dynamics simulations between α-glucosidase enzyme and mangostin compound as antidiabetic.
Maulana AF; Maksum IP; Sriwidodo S; Rukayadi Y
J Mol Model; 2024 Apr; 30(5):136. PubMed ID: 38634946
[TBL] [Abstract][Full Text] [Related]
13. Using thermodynamic integration MD simulation to compute relative protein-ligand binding free energy of a GSK3β kinase inhibitor and its analogs.
Lee HC; Hsu WC; Liu AL; Hsu CJ; Sun YC
J Mol Graph Model; 2014 Jun; 51():37-49. PubMed ID: 24858254
[TBL] [Abstract][Full Text] [Related]
14. Identification of potent EGFR-TKD inhibitors from NPACT database through combined computational approaches.
Mir SA; Muhammad A; Padhiary A; Ekka NJ; Baitharu I; Naik PK; Nayak B
J Biomol Struct Dyn; 2023; 41(21):12063-12076. PubMed ID: 36695102
[TBL] [Abstract][Full Text] [Related]
15. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
16. Different Modes of Mechanism of Gamma-Mangostin and Alpha-Mangostin to Inhibit Cell Migration of Triple-Negative Breast Cancer Cells Concerning
Sarmoko S; Novitasari D; Toriyama M; Fareza MS; Choironi NA; Itoh H; Meiyanto E
Iran J Pharm Res; 2023; 22(1):e138856. PubMed ID: 38655233
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking and molecular dynamics simulation of
Oyewusi HA; Huyop F; Wahab RA
J Biomol Struct Dyn; 2022 Mar; 40(5):1979-1994. PubMed ID: 33094694
[TBL] [Abstract][Full Text] [Related]
18. Protein phosphatase 1 regulatory inhibitor subunit 14C promotes triple-negative breast cancer progression via sustaining inactive glycogen synthase kinase 3 beta.
Jian Y; Kong L; Xu H; Shi Y; Huang X; Zhong W; Huang S; Li Y; Shi D; Xiao Y; Yang M; Li S; Chen X; Ouyang Y; Hu Y; Chen X; Song L; Ye R; Wei W
Clin Transl Med; 2022 Jan; 12(1):e725. PubMed ID: 35090098
[TBL] [Abstract][Full Text] [Related]
19. Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.
Shoaib TH; Ibraheem W; Abdelrahman M; Osman W; Sherif AE; Ashour A; Ibrahim SRM; Ghazawi KF; Miski SF; Almadani SA; ALsiyud DF; Mohamed GA; Alzain AA
PLoS One; 2023; 18(8):e0289887. PubMed ID: 37578958
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
